ATE339198T1 - Verwendung von 2-amino-2-(2-(4- octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis - Google Patents

Verwendung von 2-amino-2-(2-(4- octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis

Info

Publication number
ATE339198T1
ATE339198T1 AT00940873T AT00940873T ATE339198T1 AT E339198 T1 ATE339198 T1 AT E339198T1 AT 00940873 T AT00940873 T AT 00940873T AT 00940873 T AT00940873 T AT 00940873T AT E339198 T1 ATE339198 T1 AT E339198T1
Authority
AT
Austria
Prior art keywords
treatment
viral myocarditis
viral
prophylaxis
octylphenyl
Prior art date
Application number
AT00940873T
Other languages
English (en)
Inventor
Akira Matsumori
Original Assignee
Akira Matsumori
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akira Matsumori, Mitsubishi Pharma Corp filed Critical Akira Matsumori
Application granted granted Critical
Publication of ATE339198T1 publication Critical patent/ATE339198T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00940873T 1999-06-30 2000-06-28 Verwendung von 2-amino-2-(2-(4- octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis ATE339198T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18529799 1999-06-30

Publications (1)

Publication Number Publication Date
ATE339198T1 true ATE339198T1 (de) 2006-10-15

Family

ID=16168405

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00940873T ATE339198T1 (de) 1999-06-30 2000-06-28 Verwendung von 2-amino-2-(2-(4- octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis

Country Status (11)

Country Link
US (1) US7902261B2 (de)
EP (1) EP1201236B1 (de)
JP (1) JP4627356B2 (de)
KR (1) KR100655251B1 (de)
CN (1) CN1162149C (de)
AT (1) ATE339198T1 (de)
AU (1) AU770495B2 (de)
CA (1) CA2373833C (de)
DE (1) DE60030732T2 (de)
ES (1) ES2272293T3 (de)
WO (1) WO2001001978A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
RU2330839C2 (ru) 2002-01-11 2008-08-10 Санкио Компани, Лимитед Производные аминоспиртов или производные фосфорных кислот и фармацевтические композиции, содержащие указанные производные
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
DE202004021680U1 (de) 2003-04-08 2010-04-22 Novartis Ag Feste pharmazeutische Zusammensetzung
MXPA05014216A (es) * 2003-06-24 2006-03-13 Univ Connecticut Metodos para inhibir permeabilidad vascular y apoptosis.
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
TWI355934B (en) 2004-02-24 2012-01-11 Sankyo Co Pharmaceutical composition for treatment or prophy
KR101334511B1 (ko) 2004-12-30 2013-11-29 아스텍스 테라퓨틱스 리미티드 Ｃｄｋ, ｇｓｋ 및 오로라 키나아제의 활성을 조절하는피라졸 화합물
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
SI3103448T1 (sl) * 2006-09-26 2019-11-29 Novartis Ag Farmacevtski sestavek, ki vsebuje modulator S1P
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
PT2465492E (pt) 2007-10-12 2015-10-15 Novartis Ag Composições que compreendem moduladores de receptores de esfingosina-1-fosfato (s1p)
JP2012508215A (ja) * 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
AU2013100533B4 (en) * 2008-11-11 2013-12-12 Novartis Ag Crystalline forms of fingolimod HCL
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
WO2013176223A1 (ja) * 2012-05-23 2013-11-28 国立大学法人大阪大学 炎症性疾患治療用医薬組成物
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CN107982530B (zh) * 2017-10-23 2019-02-22 苏州大学 Semaphorin7A抗体在制备用于治疗心肌炎疾病的药物中的应用及其药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008976A1 (en) * 1992-10-08 1994-04-28 E.I. Du Pont De Nemours And Company Fungicidal and miticidal aminopyrimidines
EP0627406B1 (de) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1, 3- propandiolverbindung und immunosuppressium
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
DE69840169D1 (de) 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法

Also Published As

Publication number Publication date
CN1162149C (zh) 2004-08-18
DE60030732D1 (de) 2006-10-26
US20050234133A1 (en) 2005-10-20
KR100655251B1 (ko) 2006-12-08
AU770495B2 (en) 2004-02-26
EP1201236B1 (de) 2006-09-13
EP1201236A1 (de) 2002-05-02
EP1201236A4 (de) 2005-01-05
CA2373833C (en) 2010-03-02
CA2373833A1 (en) 2001-01-11
KR20020016860A (ko) 2002-03-06
DE60030732T2 (de) 2007-10-11
AU5570300A (en) 2001-01-22
JP2001072585A (ja) 2001-03-21
CN1359290A (zh) 2002-07-17
JP4627356B2 (ja) 2011-02-09
US7902261B2 (en) 2011-03-08
EP1201236A8 (de) 2002-10-09
WO2001001978A1 (fr) 2001-01-11
ES2272293T3 (es) 2007-05-01

Similar Documents

Publication Publication Date Title
DE60030732D1 (de) Verwendung von 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis
DE60234052D1 (de) Vorbeugung und behandlung von oxidativer-stress-erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
EA200601281A1 (ru) Азабензофуранзамещенные тиомочевины; ингибиторы репликации вирусов
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
EA200971026A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
NO20022442L (no) Legemidler for sykdommer i forbindelse med reduksjon i benmasse
DK1664016T3 (da) Terapeutiske midler, der er anvendelige til behandling af smerter
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
DE69327328D1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
DE60135904D1 (de) Arzneien zur behandlung von nervenerkrankungen
BRPI0409151A (pt) uso de derivados de 10-hidróxi-10,11-diidrocarbamazepina para o tratamento de transtornos afetivos
ATE401901T1 (de) Antikrebs- und antivirale zusammensetzung
BRPI0407140A (pt) Droga terapêutica para vìrus
BR9909870A (pt) Pirrolidinas como inibidores de neuraminidases
DK0911026T3 (da) Creatinderivater for astma
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
TR199900523T2 (xx) Vir�s k�kenli hastal�klar�n tedavisi i�in farmas�tik bile�imler.
BRPI0410657A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DE69925312D1 (de) Bupropion zur behandlung von viralen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties